Thu Hoa van
General Practice · Westminster, CANPI 1477510568
Payments from drug & device makers
Across 241 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AstraZeneca$638
- Gilead$490
- Lilly USA, LLC$443
- GSK$417
- AbbVie$412
- plus $3K from 24 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$6,723100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 54 | $1,708 |
| AstraZeneca | 17 | $638 |
| Gilead | 19 | $490 |
| Lilly USA, LLC | 16 | $443 |
| GSK | 13 | $417 |
| AbbVie(2 entities) | 12 | $412 |
| Novartis | 17 | $350 |
| Novo Nordisk | 11 | $329 |
| Pfizer | 15 | $319 |
| Bayer | 12 | $264 |
| Merck | 14 | $258 |
| Amarin Pharma, Inc. | 8 | $252 |
| Vanda Pharmaceuticals Inc. | 5 | $129 |
| Idorsia Pharmaceuticals US Inc | 1 | $121 |
| Exact Sciences | 3 | $87 |
| Johnson & Johnson(2 entities) | 3 | $72 |
| Astellas Pharma US Inc | 4 | $70 |
| Radius Health, Inc. | 2 | $48 |
| Boehringer Ingelheim | 2 | $46 |
| Redhill Biopharma Inc. | 2 | $43 |
| Seqirus USA Inc | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Optinose US, Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,730 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 130 | $130,834 |
| TradjentaLinagliptin | 112 | $115,475 |
| ProliaDenosumab | 67 | $111,582 |
| VascepaIcosapent Ethyl | 191 | $91,923 |
| FarxigaDapagliflozin Propanediol | 84 | $90,911 |
| KerendiaFinerenone | 63 | $72,937 |
| VemlidyTenofovir Alafenamide | 29 | $53,490 |
| EliquisApixaban | 62 | $51,069 |
| TrulicityDulaglutide | 27 | $48,168 |
| JanuviaSitagliptin Phosphate | 63 | $43,834 |
| OzempicSemaglutide | 23 | $43,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $40,405 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 52 | $37,163 |
| Icosapent Ethyl | 166 | $35,723 |
| LinzessLinaclotide | 42 | $33,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy, Synjardy Xr | $46 | $324,667329 claims |
| AmgenProlia | $1,708 | $111,58267 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $638 | $104,675106 claims |
| BayerKerendia | $264 | $72,93763 claims |
| MerckJanuvia, Janumet | $258 | $64,28180 claims |
| GileadVemlidy | $490 | $53,49029 claims |
| PfizerEliquis | $319 | $51,06962 claims |
| AbbVieLinzess, Creon | $412 | $48,31857 claims |
| Lilly USA, LLCTrulicity | $443 | $48,16827 claims |
| Novo NordiskOzempic | $329 | $43,11223 claims |
| GSKTrelegy Ellipta | $417 | $40,40553 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $26,01837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Westminster
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.